A Study to Assess the Acceptability and Usability of a New Device for Intradermal Vaccination

A Randomized Controlled Study to Assess the Acceptability and Usability of New Delivery Device for Intradermal Vaccination in Healthy Volunteers

The aim of this study was to assess the acceptability and usability of a newly developed intradermal device in healthy adults

Study Overview

• Status: Completed
• Conditions: Pain; Vaccination Adverse Event
• Intervention / Treatment: Device: Intradermal injection in the forearm (0,1cc NaCl 0,9%); Device: Intradermal injection in the upper arm (0,1cc NaCl 0,9%); Drug: Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)

• Study Type: Interventional
• Enrollment (Actual): 102
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Antwerp
    • Wilrijk, Antwerp, Belgium, 2650
      • University of Antwerp

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 63 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• healthy adults

Exclusion Criteria:

• people who have regular experience with needle injections, e.g. diabetic patients
• pregnant women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intradermal group; These group participants received two intradermal injections with the newly developed device, one in the forearm and one in the upper arm (deltoid region).	Device: Intradermal injection in the forearm (0,1cc NaCl 0,9%); This injection is conducted by the newly developed device.; Device: Intradermal injection in the upper arm (0,1cc NaCl 0,9%); This injection is conducted by the newly developed device in the upper arm (deltoid region).
Experimental: Intramuscular group; These group participants received one intramuscular injection in the upper arm(deltoid region) using needle and syringe and one intradermal injection in the forearm using the newly developed device.	Device: Intradermal injection in the forearm (0,1cc NaCl 0,9%); This injection is conducted by the newly developed device.; Drug: Intramuscular injection in the upper arm (0,5cc NaCl 0,9%); This injection is conducted by needle and syringe in the upper arm (deltoid region).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acceptability (e.g. pain) of an injection with an intradermal vaccine delivery device compared to an intramuscular injection with syringe and needle	Each of the volunteers was asked to complete two questionnaires: first questionnaire surveyed demographic parameters, including gender, age, health care related job or education, number of vaccinations and blood samples taken during the last 5 years, second questionnaire surveyed the experience of ID and/or IM injection, such as anxiety, pain during injection and duration of injection. Also the perception of the participant towards injections into the forearm, which could be perceived as an unnatural site for vaccination, and perception towards the need to undress for IM vaccination, i.e. preparing the upper arm for injection, was asked. The Visual Analogue Scale (1=no agreement; 10=full agreement) was used to score the statements.	1 day (directly after the injections)
Adverse events after an injection with an intradermal delivery device and/or intramuscular injection with syringe and needle	Volunteers were asked to fill a daily electronic diary for 5 days after the injections. The diary surveyed the presence of local reactions (pain at injection site, redness, swelling, ecchymosis and hardening) and systemic adverse events (headache, malaise, chills, myalgia, arthralgia, weakness/fatigue and temperature). In case of local reactions, participants were asked to measure the size of the reaction (in mm). For this purpose, a transparent ruler was provided to the participants at the study day.	during 5 days after the injections

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Usability (e.g. handling) of an injection with an intradermal vaccine delivery device compared to an intramuscular injection with syringe and needle	At the end of a study day, the nurses performing the injections received a questionnaire that assessed the usability of VAX-ID. The nurses were requested to rate the attractiveness, handling, solidity, safety and ease of use. Some questions assessed their experience relating to painful(ness), speed and injection sites. Also their thoughts on the usability by non-medical staff (with or without any manual) and on self-administration by patients were inquired. The Visual Analogue Scale (1=no agreement; 10=full agreement) was used to score the statements. An expert panel was organized in order to gather additional comments, remarks and proposed improvements on the use of the VAX-ID.	Within one day after administering the injections

Collaborators and Investigators

• Sponsor: Pierre Van Damme
• Investigators: Study Director: Pierre Van Damme, Prof., Universiteit Antwerpen

Publications and helpful links

General Publications

• Van Mulder TJ, Verwulgen S, Beyers KC, Scheelen L, Elseviers MM, Van Damme P, Vankerckhoven V. Assessment of acceptability and usability of new delivery prototype device for intradermal vaccination in healthy subjects. Hum Vaccin Immunother. 2014;10(12):3746-53. doi: 10.4161/21645515.2014.979655.

Study record dates

Study Major Dates

• Study Start: April 1, 2012
• Primary Completion (Actual): May 1, 2012
• Study Completion (Actual): May 1, 2012

Study Registration Dates

• First Submitted: October 7, 2013
• First Submitted That Met QC Criteria: October 15, 2013
• First Posted (Estimate): October 16, 2013

Study Record Updates

• Last Update Posted (Estimate): March 17, 2016
• Last Update Submitted That Met QC Criteria: March 15, 2016
• Last Verified: March 1, 2016

More Information

Terms related to this study

• Other Study ID Numbers: cev2012-vaxid